SpringWorks Therapeutics, Inc. (SWTX) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Stamford, CT, 美国. 現任CEO為 Saqib Islam.
SWTX 擁有 IPO日期為 2019-09-13, 368 名全職員工, 在 NASDAQ Global Select, 市值為 $3.54B.
SpringWorks Therapeutics, Inc. is a biopharmaceutical company founded in 2017 that acquires, develops, and commercializes medicines targeting underserved patient populations with rare diseases and cancer. The company's lead product candidate, nirogacestat, is an oral gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors, while its clinical pipeline includes mirdametinib, a MEK inhibitor being evaluated for neurofibromatosis type 1-associated plexiform neurofibromas and solid tumors, as well as BGB-3245 for BRAF-mutant cancers. SpringWorks has established strategic collaborations and licensing agreements with major pharmaceutical companies including BeiGene, GlaxoSmithKline, Pfizer, and others to advance combination therapies and expand its therapeutic capabilities. Headquartered in Stamford, Connecticut, the company focuses on developing innovative small molecule inhibitors across multiple oncology and rare disease indications.
